GS-441524-Diphosphate-Ribose Derivatives as Nanomolar Binders and Fluorescence Polarization Tracers for SARS-CoV-2 and Other Viral Macrodomains

Kewen Peng,Shamar D. Wallace,Saket R. Bagde,Jialin Shang,Ananya Anmangandla,Sadhan Jana,J. Christopher Fromme,Hening Lin

DOI: https://doi.org/10.1021/acschembio.4c00027

IF: 4.634

2024-04-23

ACS Chemical Biology

Abstract:Viral macrodomains that can bind to or hydrolyze protein adenosine diphosphate ribosylation (ADP-ribosylation) have emerged as promising targets for antiviral drug development. Many inhibitor development efforts have been directed against the severe acute respiratory syndrome coronavirus 2 macrodomain 1 (SARS-CoV-2 Mac1). However, potent inhibitors for viral macrodomains are still lacking, with the best inhibitors still in the micromolar range. Based on GS-441524, a remdesivir precursor, and our...

biochemistry & molecular biology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to develop highly effective inhibitors for SARS - CoV - 2 and other viral macrodomains. Specifically, the researchers designed and synthesized derivatives based on GS - 441524 (a precursor of the antiviral drug remdesivir), and these derivatives can bind to the macrodomain proteins of SARS - CoV - 2, Middle East respiratory syndrome coronavirus (MERS - CoV), Venezuelan equine encephalitis virus (VEEV) and chikungunya virus (CHIKV) with nanomolar - level affinity. In addition, the study also developed two highly sensitive fluorescence polarization trackers for effectively determining the binding affinity of nanomolar - level inhibitors. ### Main problems 1. **Improving binding affinity**: - The researchers improved the binding affinity of compounds to multiple viral macrodomains by introducing specific structural features (such as the 1′ - CN group and a simple benzene ring at the 1″ - OH position). - These structural features make the binding affinity of the best binder 20 to 6000 times higher than that of ADP - ribose. 2. **Developing highly effective fluorescence polarization trackers**: - Based on the above highly effective binders, the researchers developed two highly sensitive fluorescence polarization trackers (TAMRA - NDPr and TAMRA - Ph - NDPr), which can effectively determine the binding affinity of nanomolar - level inhibitors at nanomolar protein concentrations. - The use of these trackers significantly reduces the screening cost and improves the resolution of low - nanomolar - activity inhibitors. ### Solutions 1. **Structural optimization**: - Introduction of the 1′ - CN group: This group enhances the binding affinity by forming hydrogen bonds with the backbone NH of Phe156 and Asp157 in the SARS - CoV - 2 macrodomain. - Introduction of a simple benzene ring at the 1″ - OH position: This benzene ring further enhances the binding affinity through hydrophobic interactions with Ile131. 2. **Development of fluorescence polarization trackers**: - Developed two trackers, TAMRA - NDPr and TAMRA - Ph - NDPr, which show higher sensitivity and resolution in FP (fluorescence polarization) assays. - These trackers can accurately determine the binding affinity of nanomolar - level inhibitors at low concentrations, thus providing a powerful tool for future drug screening. ### Conclusion Through structural optimization and the development of fluorescence polarization trackers, the researchers not only improved the binding affinity to multiple viral macrodomains but also provided an efficient tool for future drug screening. These findings and tools will contribute to the development of more effective antiviral drugs.

GS-441524-Diphosphate-Ribose Derivatives as Nanomolar Binders and Fluorescence Polarization Tracers for SARS-CoV-2 and Other Viral Macrodomains

A Fluorescence Polarization Assay for Macrodomains Facilitates the Identification of Potent Inhibitors of the SARS-CoV-2 Macrodomain

Discovery of potent SARS-CoV-2 nsp3 macrodomain inhibitors uncovers lack of translation to cellular antiviral response

Novel Alkynylamide-Based Nonpeptidic Allosteric Inhibitors for SARS-CoV-2 3-Chymotrypsin-like Protease

Identification of FDA approved drugs and nucleoside analogues as potential SARS-CoV-2 A1pp domain inhibitor: An in silico study

Discovery of Peptidomimetic Spiropyrrolidine Derivatives As Novel 3clpro Inhibitors Against SARS-CoV-2

The Mac1 ADP-ribosylhydrolase is a Therapeutic Target for SARS-CoV-2

Identification of a series of pyrrolo-pyrimidine based SARS-CoV-2 Mac1 inhibitors that repress coronavirus replication

Structure-guided design of direct-acting antivirals that exploit the gem-dimethyl effect and potently inhibit 3CL proteases of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) and middle east respiratory syndrome coronavirus (MERS-CoV)

Two Binding Sites of SARS-CoV-2 Macrodomain 3 Probed by Oxaprozin and Meclomen

Identifying Small-Molecule Inhibitors of SARS-CoV-2 RNA-Dependent RNA Polymerase by Establishing a Fluorometric Assay

Discovery of 2-Amide-3-methylester Thiophenes that Target SARS-CoV-2 Mac1 and Repress Coronavirus Replication, Validating Mac1 as an Antiviral Target

Comparison of Binding Site of Remdesivir and Its Metabolites with NSP12-NSP7-NSP8, and NSP3 of SARS CoV-2 Virus and Alternative Potential Drugs for COVID-19 Treatment

Structural, Biophysical, and Biochemical Elucidation of the SARS-CoV-2 Nonstructural Protein 3 Macro Domain

Iterative computational design and crystallographic screening identifies potent inhibitors targeting the Nsp3 macrodomain of SARS-CoV-2

In search of SARS CoV-2 replication inhibitors: Virtual screening, molecular dynamics simulations and ADMET analysis

A Rationally Designed Synthetic Antiviral Peptide Binder Targeting the Receptor-Binding Domain of SARS-CoV-2

Oral GS-441524 derivatives: Next-generation inhibitors of SARS‐CoV‐2 RNA‐dependent RNA polymerase

Screening of Severe Acute Respiratory Syndrome Coronavirus 2 RNA-Dependent RNA Polymerase Inhibitors Using Computational Approach

Design, Synthesis, and Biological Evaluation of Trisubstituted Piperazine Derivatives as Noncovalent Severe Acute Respiratory Syndrome Coronavirus 2 Main Protease Inhibitors with Improved Antiviral Activity and Favorable Druggability

Discovery of macrocyclic covalent inhibitors for severe acute respiratory syndrome coronavirus 2 3CL protease